首页> 外国专利> Peptide Inhibiting TLR4 Signaling Pathway and Uses Thereof

Peptide Inhibiting TLR4 Signaling Pathway and Uses Thereof

机译:肽抑制TLR4信号通路及其用途

摘要

The present invention relates to a peptide that inhibits the TLR4 (Toll-like receptor 4) signaling pathway, and more specifically, binds to the TIR domain of TLR4, inhibits the secretion of pro-inflammatory cytokines, and activates NF-κB and MAPKs A peptide for inhibiting, a fusion peptide having a cell permeable peptide bound to the peptide, a TLR4 antagonist comprising the peptide or fusion peptide, and a composition for preventing or treating an autoimmune disease or inflammatory disease comprising the peptide or fusion peptide will be. The peptide according to the present invention exhibits an inhibitory effect on TLR4 and TLR3 signaling, blocks MyD88- and TRIF-dependent TLR4- pathways in many human and mouse cell lines, and is a substantial disease in rheumatoid arthritis, psoriasis and systemic lupus erythematosus mouse models Since it has a relaxing effect, it can be used as a therapeutic agent for immune-related diseases that require negative regulation of TLR.
机译:本发明涉及一种抑制TLR4(Toll样受体4)信号通路的肽,更具体地讲,其与TLR4的TIR结构域结合,抑制促炎性细胞因子的分泌,并激活NF-κB和MAPKsA。用于抑制的肽,具有结合至该肽的细胞可渗透肽的融合肽,包含该肽或融合肽的TLR4拮抗剂,以及用于预防或治疗包含该肽或融合肽的自身免疫性疾病或炎性疾病的组合物。根据本发明的肽对TLR4和TLR3信号传导具有抑制作用,在许多人和小鼠细胞系中阻断MyD88和TRIF依赖性TLR4-途径,并且是类风湿性关节炎,牛皮癣和系统性红斑狼疮小鼠的实质性疾病。模型由于具有放松作用,因此可以用作需要TLR负调节的免疫相关疾病的治疗剂。

著录项

  • 公开/公告号KR1020200084569A

    专利类型

  • 公开/公告日2020-07-13

    原文格式PDF

  • 申请/专利权人 주식회사 젠센;

    申请/专利号KR1020190000630

  • 发明设计人 최상돈;아스마 아첵;

    申请日2019-01-03

  • 分类号

  • 国家 KR

  • 入库时间 2022-08-21 10:57:26

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号